Italy
· Delayed Price · Currency is EUR Bioera Statistics
Total Valuation
Bioera has a market cap or net worth of EUR 884,555. The enterprise value is 3.86 million.
| Market Cap | 884,555 |
| Enterprise Value | 3.86M |
Important Dates
The next estimated earnings date is Friday, December 6, 2024.
| Earnings Date | Dec 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioera has 20.57 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 20.57M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +71.53% |
| Owned by Insiders (%) | 0.26% |
| Owned by Institutions (%) | 1.26% |
| Float | 17.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.44 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.62 |
| EV / Sales | 3.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.22
| Current Ratio | 0.22 |
| Quick Ratio | 0.21 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.84 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -58.80% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 287,500 |
| Profits Per Employee | -1.55M |
| Employee Count | 4 |
| Asset Turnover | 0.29 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +192.50% in the last 52 weeks. The beta is 1.14, so Bioera's price volatility has been higher than the market average.
| Beta (5Y) | 1.14 |
| 52-Week Price Change | +192.50% |
| 50-Day Moving Average | 0.06 |
| 200-Day Moving Average | 0.06 |
| Relative Strength Index (RSI) | 27.26 |
| Average Volume (20 Days) | 157,362 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bioera had revenue of EUR 1.15 million and -6.20 million in losses. Loss per share was -0.53.
| Revenue | 1.15M |
| Gross Profit | -21,000 |
| Operating Income | -3.69M |
| Pretax Income | -6.33M |
| Net Income | -6.20M |
| EBITDA | -3.66M |
| EBIT | -3.69M |
| Loss Per Share | -0.53 |
Balance Sheet
The company has 435,000 in cash and 3.01 million in debt, giving a net cash position of -2.58 million or -0.13 per share.
| Cash & Cash Equivalents | 435,000 |
| Total Debt | 3.01M |
| Net Cash | -2.58M |
| Net Cash Per Share | -0.13 |
| Equity (Book Value) | -5.23M |
| Book Value Per Share | -0.44 |
| Working Capital | -5.84M |
Cash Flow
| Operating Cash Flow | 466,000 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | -1.83% |
| Operating Margin | -320.87% |
| Pretax Margin | -550.26% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Bioera does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -321.47% |
| Shareholder Yield | -321.47% |
| Earnings Yield | -1,224.77% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on November 28, 2022. It was a reverse split with a ratio of 0.1.
| Last Split Date | Nov 28, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Bioera has an Altman Z-Score of -12.82. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12.82 |
| Piotroski F-Score | n/a |